Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

An Open Label Study of the Effects of SHR1459 in NMOSDs Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04670770
Recruitment Status : Active, not recruiting
First Posted : December 17, 2020
Last Update Posted : October 20, 2021
Sponsor:
Information provided by (Responsible Party):
Reistone Biopharma Company Limited

Brief Summary:
This is an open-label study, to evaluate the efficacy and safety of SHR1459 in participants with NMOSDs.

Condition or disease Intervention/treatment Phase
Neuromyelitis Optica Spectrum Disorders Drug: Drug - SHR1459 Phase 2

Detailed Description:

Therefore, the investigators of this study are investigating whether SHR1459 could prevent relapse of NMOSDs.

The primary objective of this study is to evaluate the effectiveness of SHR1459 in NMOSDs patients.

The secondary objectives are to determine:

The safety profile of SHR 1459 in patients with NMOSDs. Whether SHR1459 reduce MRI lesions and APQ4-Abs level.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 10 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open Label Phase II Clinical Trial Evaluating the Efficacy and Safety of SHR1459 in Adult Patients With Neuromyelitis Optical Spectrum Disorders (NMOSDs)
Actual Study Start Date : December 24, 2020
Estimated Primary Completion Date : August 31, 2022
Estimated Study Completion Date : September 30, 2022


Arm Intervention/treatment
Experimental: SHR1459
SHR1459
Drug: Drug - SHR1459
Oral Tablets taken once daily for 52 weeks




Primary Outcome Measures :
  1. Evaluate the efficacy of SHR1459 in patients with relapsing NMOSDs [ Time Frame: 52 weeks ]
    Comparison of the annualized relapse rate at 52 weeks of treatment with the annualized recurrence rate before screening.


Secondary Outcome Measures :
  1. Comparison of the annualized relapse rate at 52 weeks of treatment with the year before screening. [ Time Frame: 52 weeks ]
    Comparison of the annualized relapse rate at 52 weeks of treatment with the year before screening.

  2. Proportion of subjects who are relapse-free at week 24 and 52. [ Time Frame: 52 weeks ]
    Proportion of subjects who are relapse-free at week 24 and 52.

  3. Changes in the expanded disability status scale (EDSS) at week 4, 12, 24, 36, and 52 compared to baseline. [ Time Frame: 52 weeks ]
    Changes in the expanded disability status scale (EDSS) at week 4, 12, 24, 36, and 52 compared to baseline.

  4. Changes in low-contrast visual acuity (LCVA) score at week 4, 12, 24, 36 and 52 compared to baseline [ Time Frame: 52 weeks ]
    Changes in low-contrast visual acuity (LCVA) score at week 4, 12, 24, 36 and 52 compared to baseline.

  5. Changes in cumulative active MRI lesion count at week 24 and 52 compared to baseline. [ Time Frame: 52 weeks ]
    Changes in cumulative active MRI lesion count at week 24 and 52 compared to baseline.

  6. Changes in health related quality of life (HRQoL) at week 12, 24, 36 and 52 compared to baseline. [ Time Frame: 52 weeks ]
    Changes in health related quality of life (HRQoL) at week 12, 24, 36 and 52 compared to baseline.

  7. Changes in pain severity score (NRS) at week 4, 12, 24, 36 and 52 compared to baseline. [ Time Frame: 52 weeks ]
    Changes in pain severity score (NRS) at week 4, 12, 24, 36 and 52 compared to baseline.

  8. Changes in serum AQP4-IgG titer from baseline at 4, 12, 24, 36, 52 weeks. [ Time Frame: 52 weeks ]
    Changes in serum AQP4-IgG titer from baseline at 4, 12, 24, 36, 52 weeks.

  9. Changes in the absolute value of B lymphocytes and total immunoglobulins (IgA, IgG and IgM) from baseline after 12, 24, and 52 weeks of treatment. [ Time Frame: 52 weeks ]
    Changes in the absolute value of B lymphocytes and total immunoglobulins (IgA, IgG and IgM) from baseline after 12, 24, and 52 weeks of treatment

  10. The plasma concentration of SHR1459 and its metabolite SHR1459-02 in NMOSD patients. [ Time Frame: 52 weeks ]
    The plasma concentration of SHR1459 and its metabolite SHR1459-02 in NMOSD patients



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. 18-75 years of age.
  2. Diagnosis of AQP4-IgG positive NMOSD according to IPND diagnostic criteria 2015 at screening.
  3. Having a documented history of 2 or more NMOSD relapse required rescue therapy(ies) within the last 12 months.
  4. Subjects must be stable treatment (if any) for more than 1 month before starting the IP treatment, which is defined as follows:- Expanded disability status scale (EDSS) score≦7.5
  5. Written informed consent obtained before any study procedure.
  6. Subjects are willing and able to comply with the visit schedule and treatment plan, laboratory tests and other study procedures.

Exclusion Criteria:

  1. Allergic to the investigative product or any ingredient in the investigative product.
  2. Past or current malignancy, except for cutaneous non-metastatic basal cell carcinoma or squamous cell carcinoma that has been adequately treated or removed
  3. The subject currently has a central nervous system (CNS) disease that may affect the assessment of NMOSD;
  4. Severe and uncontrolled conditions that the investigator determines may affect subjects' safety, trial compliance, evaluation of the end point, or the need to use medications not permitted in the protocol;
  5. The investigator judges that the subject has a disease that affects the absorption, distribution, metabolism and excretion of the drug;
  6. The subjects had any major clinical infection and was hospitalized or treated with parenteral antibiotics within 1 month before screening; Or other infections that investigator thought might aggravate as a result of participating in the study;
  7. The subject may have an active, latent or undertreated Mycobacterium tuberculosis (ie, tuberculosis [TB]) infection, defined as follows:

    • The result of QuantiFERON-TB Gold (QFT Gold test) was positive or the result of T-SPOT.TB was positive within 3 months before screening/screening period.
    • Or chest imaging examinations suggest the presence of active tuberculosis infection within 3 months before screening / during the screening period;
    • The result of QuantiFERON-TB Gold (QFT Gold test) was positive or the result of T-SPOT.TB was positive within 3 months before screening/screening period.
    • Or chest imaging examinations suggest the presence of active tuberculosis infection within 3 months before screening / during the screening period;
  8. Positive laboratory tests related to human immunodeficiency virus (HIV) or hepatitis B virus or hepatitis C virus;
  9. Have received BTK inhibitors (e.g. ibrutinib) at any time in the past.
  10. Received B-cell targeted therapy (such as rituximab) within 12 weeks before the first administration.
  11. Received biological agents such as eculizumab, tocilizumab, Satralizumab, Alemtuzumab, Natalizumab within 12 weeks before the first administration;
  12. Subjects who may receive any live attenuated vaccine during the screening period or have received any live virus vaccine within 8 weeks prior to initial administration;
  13. Any concomitant disease other than NMOSD that requires glucocorticoid therapy (oral or IV) within the 6 months prior to screening.
  14. Abnormal and clinically significant ECG examination during screening.
  15. Alanine glutamate aminotransferase (ALT)>2 times the upper limit of normal (ULN) and/or glutamate aspartate aminotransferase (AST)>2 times ULN and/or bilirubin>2 times ULN during the screening period ULN;
  16. Abnormal white blood cell count, neutrophil count, lymphocyte count, or platelet count during the screening period are considered unsuitable for participating in the study after the investigator's assessment (refer to the following criteria):

    • Hemoglobin <100 g/L or hematocrit <30%;
    • White blood cell (WBC) count<3.0×109/L (<3000/mm3) or ANC<1.2×109/L (<1200/mm3);
    • Lymphocytes <0.8×109/L (<800/mm3);
    • Platelet count<100×109/L (<100,000/mm3)
  17. eGFR≤60 ml/min (calculated according to Cockcroft-Gault) or receiving dialysis during the screening period.
  18. Unable to undergo MRI scans. History of clinically significant CNS trauma (e.g. traumatic brain injury, cerebral contusion, spinal cord compression)
  19. Pregnant or breastfeeding women;
  20. Use of an investigational drug or other experimental therapy within 4 weeks, 5 pharmacokinetic half-lives, or the duration of biological effect (whichever is longer) prior to screening.
  21. Any other conditions in which the investigator or sponsor believes that the subject is not suitable for inclusion in the study.

    -


Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04670770


Locations
Layout table for location information
China
Xiangya Hospital Of Central South University
Changsha, China
West China Hospital Sichuan University
Chengdu, China
Lanzhou University Second Hospital
Lanzhou, China
People's Hospital of Rizhao
Rizhao, China
Huashan Hospital Affiliated To Fudan University
Shanghai, China
First Hospital Of Shanxi Medical University
Taiyuan, China
Tangdu Hosiptal
Xi'an, China
The First Affiliated Hospital Of Zhengzhou University
Zhengzhou, China
Sponsors and Collaborators
Reistone Biopharma Company Limited
Layout table for additonal information
Responsible Party: Reistone Biopharma Company Limited
ClinicalTrials.gov Identifier: NCT04670770    
Other Study ID Numbers: RSB20621
First Posted: December 17, 2020    Key Record Dates
Last Update Posted: October 20, 2021
Last Verified: December 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Neuromyelitis Optica
Myelitis, Transverse
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Optic Neuritis
Optic Nerve Diseases
Cranial Nerve Diseases
Demyelinating Diseases
Eye Diseases
Autoimmune Diseases
Immune System Diseases